TY - JOUR
T1 - Breast Cancer Germline Genetic Counseling and Testing for Populations of African Heritage Globally
T2 - A Scoping Review on Research, Practice, and Bioethical Considerations
AU - Iwai, Yoshiko
AU - Toumbou, Kadiata
AU - Zuze, Takondwa
AU - Morgan, Jenny S.
AU - Simwinga, Lusayo
AU - Wright, Sarah T.
AU - Fedoriw, Yuri
AU - Oladeru, Oluwadamilola T.
AU - Balogun, Onyinye D.
AU - Roberson, Mya L.
AU - Olopade, Olufunmilayo I.
AU - Tomoka, Tamiwe
AU - Elmore, Shekinah N.C.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - PURPOSE: Despite the disproportionately high risk of breast cancer among women of African heritage, little is known about the facilitators and barriers to implementing germline genetic testing and counseling (GT/C). METHODS: This scoping review followed guidelines recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews. Published manuscripts from database inception through 2021 were sourced from PubMed, Cumulative Index to Nursing and Allied Health Literature via EBSCO, Embase, Cochrane Library, and Scopus. Search terms were used to retrieve articles addressing (1) African heritage, (2) breast cancer, and (3) GT or GC. The screening involved abstract and title review and full-text review. Data were extracted for all articles meeting the inclusion criteria. RESULTS: A total of 154 studies were included. Most studies that took place were conducted in the United States (71.4%), and most first authors (76.9%) were from the United States. GT was conducted in 73 (49.7%) studies. BRCA1/BRCA2 were the most commonly studied genes for germline mutations. GC was conducted in 49 studies (33.3%), and perspectives on GC were evaluated in 43 (29.3%). The use of racial/ethnic categories varied broadly, although African American was most common (40.1%). Racism was mentioned in three studies (2.0%). CONCLUSION: There is a growing body of literature on GT/C for breast cancer in women of African heritage. Future studies on GT/C of African populations should consider increased clarity around racial/ethnic categorizations, continued community engagement, and intentional processes for informed consent.
AB - PURPOSE: Despite the disproportionately high risk of breast cancer among women of African heritage, little is known about the facilitators and barriers to implementing germline genetic testing and counseling (GT/C). METHODS: This scoping review followed guidelines recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews. Published manuscripts from database inception through 2021 were sourced from PubMed, Cumulative Index to Nursing and Allied Health Literature via EBSCO, Embase, Cochrane Library, and Scopus. Search terms were used to retrieve articles addressing (1) African heritage, (2) breast cancer, and (3) GT or GC. The screening involved abstract and title review and full-text review. Data were extracted for all articles meeting the inclusion criteria. RESULTS: A total of 154 studies were included. Most studies that took place were conducted in the United States (71.4%), and most first authors (76.9%) were from the United States. GT was conducted in 73 (49.7%) studies. BRCA1/BRCA2 were the most commonly studied genes for germline mutations. GC was conducted in 49 studies (33.3%), and perspectives on GC were evaluated in 43 (29.3%). The use of racial/ethnic categories varied broadly, although African American was most common (40.1%). Racism was mentioned in three studies (2.0%). CONCLUSION: There is a growing body of literature on GT/C for breast cancer in women of African heritage. Future studies on GT/C of African populations should consider increased clarity around racial/ethnic categorizations, continued community engagement, and intentional processes for informed consent.
UR - http://www.scopus.com/inward/record.url?scp=85176421892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85176421892&partnerID=8YFLogxK
U2 - 10.1200/GO.23.00154
DO - 10.1200/GO.23.00154
M3 - Review article
C2 - 37944088
AN - SCOPUS:85176421892
SN - 2378-9506
VL - 9
SP - e2300154
JO - JCO Global Oncology
JF - JCO Global Oncology
ER -